 COPENHAGEN, Denmark, Sept. 01, 2021 GLOBE NEWSWIRE -- Ascendis Pharma AS Nasdaq: ASND, a biopharmaceutical company that utilizes its innovative TransConTM technologies to potentially create new treatments that make a meaningful difference in patients lives, today announced the pricing of its underwritten public offering of 2,500,000 American Depositary Shares ADSs, each of which represents one ordinary share of Ascendis, at a price to the public of 160.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about September 7, 2021 subject to customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 375,000 ADSs at the public offering price, less the underwriting commissions. 